 Subjects will be randomly assigned to receive either an encapsulated ethyl-EPA supplement 2 gday 2X500 mg capsules twice daily Laxdale Ltd., or placebo medicinal liquid paraffin BP 2 gday, in addition to the medication that they had been receiving, for the duration of the study. Ethyl EPA is a highly purified derivative of fish-oil. The Food and Drug Administration has affirmed the status of fish-oil as generally recognised as safe with EPA doses up to 3 gday. Trial supplies will be packed by an independent contract clinical trials supplies company DHP, who will prepare the placebo and active packs for the entire trial and assign the randomisation numbers to the packs. The randomisation code will be broken after completion of the trial. 